The rapid demise of Silicon Valley Bank put an unwelcome spotlight on the financial position of many small biotechnology companies that relied on the storied lender.
But to the people who form and build startups, SVB’s collapse is a sidebar to a longer-brewing threat: a tightening cash crunch for a generation of young drugmakers. READ MORE